Podcasts Health & Fitness Medicine NEJM Interviews NEJM Interview: Dr. David Asch on why requiring informed consent for trials that pose minimal risk to participants can do more harm than good.

NEJM Interview: Dr. David Asch on why requiring informed consent for trials that pose minimal risk to participants can do more harm than good.

Published: Oct. 11, 2017, 3:01 p.m.

b'Dr. David Asch is executive director of the Center for Health Care Innovation at the University of Pennsylvania. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. D.A. Asch, T.A. Ziolek, and S.J. Mehta. Misdirections in Informed Consent - Impediments to Health Care Innovation. N Engl J Med 2017;377:1412-4.'